Document is current
Any future updates will be listed below
-
Authors
Robledo-Montaña, Javier http://orcid.org/0000-0002-6975-3452
Díaz-García, César http://orcid.org/0009-0006-2019-8570
Martínez, María http://orcid.org/0000-0002-6308-4243
Ambrosio, Nagore http://orcid.org/0000-0001-9837-5393
Montero, Eduardo http://orcid.org/0000-0003-2525-8529
Marín, María José http://orcid.org/0000-0003-0206-4756
Virto, Leire http://orcid.org/0000-0002-3376-5232
Muñoz-López, Marina http://orcid.org/0000-0003-4817-9639
Herrera, David http://orcid.org/0000-0002-5554-2777
Sanz, Mariano http://orcid.org/0000-0002-6293-5755
Leza, Juan Carlos http://orcid.org/0000-0002-9901-0094
García-Bueno, Borja http://orcid.org/0000-0001-7320-1530
Figuero, Elena http://orcid.org/0000-0002-3129-1416
Martín-Hernández, David http://orcid.org/0000-0003-0195-2604
-
Funding
Funding for this research was provided by:
MINECO-FEDER Funds (PID2019-109033RB-100, PID2019-109033RB-100)
CIBERSAM/ISCIII
Santander-University Complutense of Madrid Projects (PR41/17–20979)
- License Information
-
More Information
Article History
Received: 7 March 2024
Accepted: 29 August 2024
First Online: 8 September 2024
Declarations
:
: This study was designed according to the modified ARRIVE guidelines 2.0 for preclinical in vivo research [] and following Spanish and European Union regulations (European Communities Council Directive 86/609/EEC). The in vivo experimental part of the study was carried out in the Experimental Animal Center of the Complutense University of Madrid after its protocol was approved by the regional authorities (PROEX 087/18) and the Ethical Committee of Animal Experimentation.
: Not applicable.
: The authors declare no competing interests.
